 |
|
 |
|
| MarketVIEW: E.coli (ExPEC) vaccines |
|
|
|
Published: September 2018
Extra intestinal pathogenic E.coli (ExPEC) is a member of the Enterobacteriaceae bacterial family. It is a leading cause of
healthcare-associated (HCA) infections such as bacteraemia, urinary tract infections, neonatal sepsis and meningitis. For
bacteraemias, based on a principal diagnosis from US hospital discharge data, there were an 96,560 E. coli bacteraemias in
2013 compared to 46,140 in 2000, an increase of 109% Although the number Streptococcal, Staphylococcal and
Pneumococcal bacteraemias also increased over the same time period, in 2009, E. coli overtook Staphylococcus as the leading
cause of bacteraemia. Importantly, carbapenem-resistant E. coil is also considered an urgent threat according to the US CDC.
E.coli is also a common cause of community-acquired, uncomplicated UTIs, which are a common cause of US emergency
department and primary care visits. According to NHANES III, around 12% of women reported a UTI in the last 12 months.
Currently, there is no vaccine to prevent ExPEC infections. Janssen Pharmaceuticals is co-developing JNJ-63871860 or 860/ExPEC-4V, a 4-valent O antigen conjugate vaccine (the O antigen forms part of the E. coli lipopolysaccharide), currently in Phase II development.
The company have reported promising safety and immunogenicity data that warrants further investigation. Other approaches such as subunit or whole vaccines have been under investigation but are not currently in active development.
This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential
commercial value of ExPEC vaccines across major Western markets to 2035. Indications considered are the prevention of invasive ExPEC
disease in >18 yrs (risk and non-risk) and prevention of recurrent UTIs in females 18-64 yrs.The model contains value ($ m) and
volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. LO/BASE/HI forecast
scenarios are included based upon the level of populations targeted by a potential vaccine.
THE FULL PRODUCT IS A EXECUTIVE PRESENTATION AND A FORECAST MODEL
To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%.
Please review the TERMS and CONDITIONS of purchase.
|
|
|
|
|
|
